Baxter (BAX) EVP, Pharma Group President to resign Dec 1, 2025

Baxter International Inc. announced a leadership change: Alok Sonig has resigned as Executive Vice President and Group President, Pharmaceuticals.

Rhea-AI Filing Summary

Baxter International Inc. announced a leadership change: Alok Sonig has resigned as Executive Vice President and Group President, Pharmaceuticals. His resignation is effective December 1, 2025, and he is departing to join a company in the healthcare industry.

The update was disclosed in a current report and pertains only to this executive transition. Baxter’s common stock trades on the NYSE under BAX, and its 1.3% Global Notes due 2029 trade as BAX 29 on the NYSE.

Insights

Healthcare leadership analyst

Senior pharma leader resigns; transition effective Dec 1, 2025.

Baxter disclosed that Alok Sonig will step down as EVP and Group President, Pharmaceuticals, effective December 1, 2025. The filing states he is leaving to join a company in the healthcare industry.

Subsequent disclosures may provide information on succession and any segment leadership updates tied to the December 1, 2025 effective date.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Baxter (BAX) disclose in this update?

Baxter reported that Alok Sonig resigned as Executive Vice President and Group President, Pharmaceuticals, effective December 1, 2025.

Why is Alok Sonig leaving Baxter (BAX)?

He notified the company that he is resigning to join a company in the healthcare industry.

When is the resignation of Baxter’s EVP, Pharmaceuticals, effective?

The resignation is effective December 1, 2025.

What is Baxter’s trading symbol and exchange?

Baxter’s common stock trades on the NYSE under the symbol BAX.

Which Baxter debt security is listed and where?

The 1.3% Global Notes due 2029 trade on the NYSE under BAX 29.

What form reported this Baxter (BAX) event?

The event was disclosed in a Form 8-K under Item 5.02.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 09:02 AM EST Learn about SEC filing dates

0000010456false00000104562025-11-052025-11-050000010456bax:CommonStock1.00PerValueMemberexch:XNYS2025-11-052025-11-050000010456bax:CommonStock1.00PerValueMemberexch:XCHI2025-11-052025-11-050000010456bax:GlobalNotes13Due2029Memberexch:XNYS2025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 5, 2025

Baxter International Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-4448			36-0781620
(Commission File Number)			(I.R.S. Employer Identification No.)
One Baxter Parkway, Deerfield, Illinois			60015
(Address of principal executive offices)			(Zip Code)
(224)948-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $1.00 par value

BAX (NYSE)

New York Stock Exchange

1.3% Global Notes due 2029

BAX 29

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:   ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 5, 2025, Alok Sonig notified Baxter International Inc. (the “Company”) of his decision to resign as the Company’s Executive Vice President and Group President, Pharmaceuticals, effective as of December 1, 2025, to join a company in the healthcare industry.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 12, 2025			BAXTER INTERNATIONAL INC.
			By:			/s/ Ellen K. Bradford
			Name:			Ellen K. Bradford
			Title:			Senior Vice President and Corporate Secretary